Currently assisting with coordination of POINT (Platelet-Oriented Inhibition in New TIA and minor ischemic stroke Trial and ZZ-3K3A-201 (NN104): A multi-center, Phase 2 study using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator (tPA), mechanical thrombectomy, or both in moderate to severe acute ischemic stroke research trials.
Use of the MOCA for Patients Presenting to a Memory Disorder's Clinic
Author(s): Lisa Boyle, Jen Richard
,Date Published: 1/1/2009
Donepezil in the treatment of severe Alzheimer's disease
Author(s): Jennifer Richard, Kelly Cosman, Anton Porsteinsson
Publisher: Aging Health
Date Published: 8/1/2007